Skip to Content

Tavaborole topical Pregnancy and Breastfeeding Warnings

Tavaborole topical is also known as: Kerydin

Medically reviewed on January 22, 2018

Tavaborole topical Pregnancy Warnings

Animal studies have revealed evidence of embryofetal mortality and toxicity, and skeletal malformations with oral administration. With topical administration, a decrease in fetal bodyweight was noted at a drug solution of 10%. No effects on fertility were observed in male and female rats administered oral doses. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: C

See references

Tavaborole topical Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Kerydin (tavaborole topical)." Anacor Pharmaceuticals, Inc., Palo Alto,, CA.

References for breastfeeding information

  1. "Product Information. Kerydin (tavaborole topical)." Anacor Pharmaceuticals, Inc., Palo Alto,, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide